

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

Haoqiang Ying,^{1,2,15} Alec C. Kimmelman,^{3,15,*} Costas A. Lyssiotis,^{4,8,15} Sujun Hua,^{1,2} Gerald C. Chu,^{1,2,9} Eliot Fletcher-Sananikone,^{1,2} Jason W. Locasale,^{4,8} Jaekyoung Son,³ Hailei Zhang,¹ Jonathan L. Coloff,⁵ Haiyan Yan,^{1,2} Wei Wang,^{1,2,10} Shujuan Chen,¹ Andrea Viale,^{1,2} Hongwu Zheng,^{1,2} Ji-hye Paik,^{1,2} Carol Lim,^{1,2} Alexander R. Guimaraes,¹² Eric S. Martin,^{1,2} Jeffery Chang,^{1,2} Aram F. Hezel,^{1,2} Samuel R. Perry,^{1,2} Jian Hu,^{1,2} Boyi Gan,^{1,2} Yonghong Xiao,¹ John M. Asara,^{6,8} Ralph Weissleder,^{4,12} Y. Alan Wang,^{1,2} Lynda Chin,^{1,2,11,13} Lewis C. Cantley,^{4,8} and Ronald A. DePinho^{1,2,7,14,*}

¹Belfer Institute for Applied Cancer Science

²Department of Medical Oncology

³Division of Genomic Stability and DNA Repair, Department of Radiation Oncology Dana-Farber Cancer Institute, Boston, MA 02215, USA

⁴Department of Systems Biology

⁵Department of Cell Biology

⁶Department of Medicine

⁷Department of Genetics

Harvard Medical School, Boston, MA 02115, USA

⁸Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA

⁹Department of Pathology

¹⁰Division of Gastroenterology

¹¹Department of Dermatology

Brigham and Women's Hospital, Boston, MA 02115, USA

¹²Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA

¹³Department of Genomic Medicine

¹⁴Department of Cancer Biology

University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

¹⁵These authors contributed equally to this work

*Correspondence: alec_kimmelman@dfci.harvard.edu (A.C.K.), rdepinho@mdanderson.org (R.A.D.)

DOI 10.1016/j.cell.2012.01.058

SUMMARY

Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting role is highly context dependent. Oncogenic *Kras* mutation is the signature event in pancreatic ductal adenocarcinoma (PDAC), serving a critical role in tumor initiation. Here, an inducible *Kras*^{G12D}-driven PDAC mouse model establishes that advanced PDAC remains strictly dependent on *Kras*^{G12D} expression. Transcriptome and metabolomic analyses indicate that *Kras*^{G12D} serves a vital role in controlling tumor metabolism through stimulation of glucose uptake and channeling of glucose intermediates into the hexosamine biosynthesis and pentose phosphate pathways (PPP). These studies also reveal that oncogenic *Kras* promotes ribose biogenesis. Unlike canonical models, we demonstrate that *Kras*^{G12D} drives glycolysis intermediates into the nonoxidative PPP, thereby decoupling ribose biogenesis from NADP/NADPH-mediated redox control. Together,

this work provides *in vivo* mechanistic insights into how oncogenic *Kras* promotes metabolic reprogramming in native tumors and illuminates potential metabolic targets that can be exploited for therapeutic benefit in PDAC.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers with a 5-year survival rate of ~5% (Hidalgo, 2010). Malignant progression from pancreatic intraepithelial neoplasia (PanINs) to invasive and metastatic disease is accompanied by the early acquisition of activating mutations in the *KRAS* oncogene, which occurs in >90% of cases, and subsequent loss of tumor suppressors including *INK4A/ARF*, *TP53*, and *SMAD4* (Hezel et al., 2006). Genetically engineered mouse models (GEMM) have provided evidence for oncogenic *Kras* (*Kras*^{G12D}) as a major driver in PDAC initiation, with the aforementioned tumor suppressor genes constraining progression (Aguirre et al., 2003; Guerra et al., 2003; Hingorani et al., 2003). Although shRNA extinction of *Kras* expression as well as pharmacological inhibition of its effectors can impair growth of human PDAC lines,

clinical trials of drugs targeting key components of the RAS-MAPK pathway have shown meager responses (Rinehart et al., 2004; Singh and Settleman, 2009). The paucity of clinical progress may relate to a number of factors including the lack of a tumor maintenance role for oncogenic *Kras*, redundancy in downstream signaling surrogates, suboptimal penetration of the drug into the tumor, and/or tumor plasticity owing to a myriad of genomic alterations and intratumoral heterogeneity (Hidalgo, 2010).

Constitutive *Kras*^{G12D} signaling drives uncontrolled proliferation and enhances survival of cancer cells through the activation of its downstream signaling pathways, such as the MAPK and PI3K-mTOR pathways (Gysin et al., 2011). To meet the increased anabolic needs of enhanced proliferation, cancer cells require both sufficient energy and biosynthetic precursors as cellular building blocks to fuel cell growth. In cancer cells, metabolic pathways are rewired in order to divert nutrients, such as glucose and glutamine, into anabolic pathways to satisfy the demand for cellular building blocks (Vander Heiden et al., 2009). Accumulating evidence indicates that the reprogramming of tumor metabolism is under the control of various oncogenic signals (Levine and Puzio-Kuter, 2010). The Ras oncogene in particular has been shown to promote glycolysis (Racker et al., 1985; Yun et al., 2009). However, the mechanisms by which oncogenic *Kras* coordinates the shift in metabolism to sustain tumor growth, particularly in the tumor microenvironment, and whether specific metabolic pathways are essential for *Kras*-mediated tumor maintenance remain areas of active investigation. Here, we generated an inducible oncogenic *Kras* model of PDAC and establish that this gene is essential for tumor maintenance in vivo. Integrated transcriptomic, biochemical, and metabolomic analyses reveal a fundamental role of the *Kras* oncogene in reprogramming tumor metabolism by selectively activating biosynthetic pathways to maintain tumor growth.

RESULTS

Kras^{G12D} Is Essential for PDAC Maintenance

To control *Kras*^{G12D} expression in a temporal- and tissue-specific manner, we generated a conditional *Kras*^{G12D} transgene under the control of a tet-operator with a lox-stop-lox (LSL) cassette inserted between the promoter and the start codon of the *Kras*^{G12D} open reading frame (*tetO_Lox-Stop-Lox-Kras*^{G12D}, designated *tetO_LKras*^{G12D}) (Figure S1A available online). These mice were crossed to *ROSA26-LSL-rtTA-IRES-GFP* (*ROSA_{rtTA}*) (Belteki et al., 2005) and *p48-Cre* (Kawaguchi et al., 2002) mice to enable pancreas-specific and doxycycline (doxy)-inducible expression of *Kras*^{G12D} (Figure S1B). This triple transgenic strain is designated hereafter as *iKras*. Doxy treatment effectively induced oncogenic *Kras* expression and activity (Figures S1C and S1D), but did not substantially increase total *Kras* expression at the mRNA or protein levels (Figures S1C and S1E). Extinction of the *Kras*^{G12D} transgene occurs within 24 hr following doxy withdrawal (Figures S1C and S1D).

Consistent with the role of *Kras*^{G12D} as a driver of PDAC initiation (Hezel et al., 2006), doxy induction provokes acinar-to-ductal metaplasia and PanIN lesions within 2 weeks (Figure S1F). Similar to the *LSL-Kras*^{G12D} knock-in model, induction of the *Kras*^{G12D} transgene leads to infrequent occurrence of invasive

PDAC after long latency (35–70 weeks) (Figure S1F), suggesting comparable biological activity of the *Kras*^{G12D} alleles and the need for additional genetic events for tumor progression. To enable full malignant progression and assess the tumor maintenance role of *Kras*^{G12D} in advanced malignancies, we crossed *iKras* and conditional *p53* knockout (*p53*^{L/L}) alleles (Marino et al., 2000). Following doxy treatment at 3 weeks of age, all *iKras* *p53*^{L/+} mice succumbed to PDAC between 11 and 25 weeks of age (median survival, 15 weeks), whereas the doxy-treated *iKras* *p53*^{L/L} mice succumbed to PDAC more rapidly with a median survival of 7.9 weeks (Figure 1A). The *iKras* *p53* mutant tumors exhibited features commonly found in human PDAC, including glandular tumor structures, exuberant stroma, local invasion into surrounding structures such as the duodenum, and distant metastases to the liver and lung (Figure 1B). Histological analysis documented invasive PDAC in 8/8 *iKras* *p53*^{L/+} mice at 8 weeks after induction (Figure S1G). As such, we assessed the impact of *Kras*^{G12D} extinction on tumor biology and maintenance at 9 weeks after induction. As shown in Figure 1C, *Kras*^{G12D} extinction led to rapid tumor regression with morphological deterioration of tumor cells and rapid degeneration of stromal elements starting 48 hr and peaking at 72 hr following doxy withdrawal. After 1 week of doxy withdrawal, MRI showed a reduction in tumor mass of ~50%, whereas PET/CT showed complete loss of fluorodeoxyglucose (FDG) uptake (Figures 1D and 1E). On the histopathological level, virtually all malignant components of the tumor regressed with the remaining pancreata displaying collagen deposition surrounding few remnant ductal structures (Figure 1C). Correspondingly, tumor regression was accompanied by decreased tumor cell proliferation (BrdU incorporation) and increased apoptosis (Caspase-3 activation) 2–3 days after doxy withdrawal, culminating in complete loss of tumor cell proliferation at 1 week off doxy (Figures 2A and S2A; data not shown). Moreover, *Kras*^{G12D} extinction effected dramatic changes in the tumor stroma as evidenced by a reduction in pancreatic stellate cells (marked by SMA staining) (Figure 2A), which is a prominent component of the classical stromal reaction in PDAC. This indicates that oncogenic *Kras* has significant non-cell-autonomous effects on the stromal compartment. The in vivo findings of decreased proliferation and increased apoptosis of the epithelial compartment parallel cell culture assays, such as loss of clonogenic growth of primary tumor cells (Figure S2B), consistent with a role for cell-autonomous mechanisms contributing to tumor regression. Together, these findings establish that *Kras*^{G12D} expression is required for PDAC maintenance in this autochthonous model, supporting both the proliferation and viability of tumor cells and its associated stroma.

These biological changes aligned with changes in prototypical *Kras* signaling components, including a decrease in MAPK signaling measured by phospho-Erk as early as 24 hr following doxy withdrawal (Figure 2B), preceding any obvious changes in tumor morphology. Decreased phospho-Erk was followed by dampened mTOR signaling, as evidenced by a decreased phospho-S6 in tumor cells, although the signal remained high in some stromal cells (Figure 2B). These in vivo signaling patterns matched those seen in cultured tumor cells (Figure S2C). As expected, *LSL-Kras*^{G12D} *p53*^{L/+} primary tumor cell cultures showed no doxy-dependent signaling changes (Figure S2D).




Figure 1. $Kras^{G12D}$ Inactivation Leads to Rapid Tumor Regression

(A) Kaplan-Meier overall survival analysis for mice of indicated genotypes. Cohort size for each genotype is indicated. Arrow: time point for starting doxy treatment. On: mice were fed with doxy-containing water from 3 weeks of age. Off: mice were maintained doxy-free.

(B) Histopathological characterization of PDAC from $iKras p53^{L/+}$ mice showing (i) typical ductal adenocarcinoma with well-differentiated glandular tumor cells and strong stromal reaction; (ii) local invasion of tumor cells (right of the dotted line) into duodenum wall; (iii) liver metastasis (arrow); and (iv) lung metastasis (arrow).

(C) H&E staining shows histological changes of PDAC at the indicated time points after doxy withdrawal. Scale bar represents 100 μ m.

(D) MRI scan illustrating tumor (area within the dotted line) shrinkage following 7 days of doxy withdrawal.

(E) ^{18}F -FDG-PET/CT scan of tumor bearing mice at day 0 and day 7 upon doxy withdrawal. *, tumor; Kd, kidney; Bc, bladder dome.

See also Figure S1.

$Kras^{G12D}$ Regulates Multiple Metabolic Pathways at the Transcriptional Level

To gain further mechanistic insight into $Kras^{G12D}$ -mediated tumor maintenance, transcriptomic analysis was conducted using orthotopic $iKras p53$ null tumors generated from five independent primary tumor lines. Importantly, these orthotopic

tumors faithfully recapitulated histological and molecular features of the primary tumors (Figure S3A). To audit proximal molecular changes linked to $Kras^{G12D}$ extinction, tumors were harvested at 24 hr following doxy withdrawal. This time point shows documented loss of Ras activity (Figure 3A), yet absence of morphological changes or a significant decrease in




Figure 2. Histopathological Characterization of Tumor Regression upon $Kras^{G12D}$ Inactivation

(A) $iKras^{p53^{L/L}}$ mice were fed with doxy-containing water for 9 weeks from 3 weeks of age. The mice were pulled from doxy treatment at the indicated days and injected with BrdU. Pancreatic tumors were stained with antibodies to BrdU (panels i, iv, vii, x), cleaved-caspase3 (panels ii, v, viii, xi), and SMA (panels iii, vi, ix, xii).

(B) Pancreatic tumors from (A) were stained with antibodies to phospho-Erk (panels i, iii, v, vii) and phospho-S6 (panels ii, iv, vi, viii). Scale bar represents 100 μ m. See also Figure S2.

proliferation (Figure S2A). Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) of the in vivo and in vitro $Kras^{G12D}$ transcriptome using the KEGG gene sets showed striking representation of metabolic processes, including the downregulation of steroid biosynthesis, pyrimidine metabolism, O-glycan biosynthesis, and glycan structures biosynthesis pathways (Figures 3B and 3C and Table S1). Moreover, xenograft tumors and cultured parental lines exhibited significant correlation in expression levels for the differentially expressed genes (Figure S3B), suggesting that the cultured tumor cell lines may serve to complement tumor studies in vivo.

$Kras^{G12D}$ Enhances Glycolytic Flux

To interrogate the role of $Kras^{G12D}$ in the regulation of tumor metabolism, targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) metabolomic studies were performed to comprehensively characterize metabolic alterations immediately following $Kras^{G12D}$ withdrawal (Yuan et al., 2012). This analysis revealed that $Kras^{G12D}$ extinction effected significant metabolic changes involving multiple pathways, the most significant of which are intermediates in glucose metabolism (Figures 4A and 4B). Consistent with the function of $Kras^{G12D}$ in the regulation of glycolysis (Racker et al., 1985), $Kras^{G12D}$ extinction was accompanied by a significant drop in glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), and fructose-1,6-bisphosphate (FBP) with minimal changes to the remaining components in glycolysis (Figure 4E). In addition, $Kras^{G12D}$ extinction led to decreased glucose uptake and lactate produc-

tion (Figures 4C and 4D), demonstrating that oncogenic $Kras^{G12D}$ enhances glycolytic flux in PDAC. These metabolic changes were highly concordant with the gene expression changes from the transcriptional profiles, which showed downregulation of the glucose transporter (*Glut1/Slc2a1*) and several other rate-limiting glycolytic enzymes *Hk1*, *Hk2*, and *Pfk1*, as well as *Ldha*, the enzyme responsible for converting pyruvate to lactate (Figures 4A and S4A). These data suggest that $Kras^{G12D}$ is essential for glucose utilization in this model through the regulation of multiple rate-limiting steps including those that govern glucose uptake and subsequent metabolism. Interestingly, we also observed that $Kras^{G12D}$ inactivation was

not accompanied by significant alterations to TCA cycle intermediates (Figure S4B). This finding is in line with a model whereby proliferating cells divert glucose metabolites into anabolic processes (e.g., nucleotide and lipid biosynthesis) whereas alternative carbon sources are utilized to fuel the TCA cycle (Vander Heiden et al., 2009). Indeed, consistent with previous reports (Gao et al., 2009; Wise et al., 2008), glutamine is the major carbon source for the TCA cycle in the $Kras^{G12D}$ -driven PDAC cells as shown by uniformly labeled (U - $^{13}C_6$)-glucose and U - $^{13}C_5$ -glutamine tracing (Figure S4C).

$Kras^{G12D}$ Activates the Hexosamine Biosynthesis Pathway and Protein Glycosylation

Because $Kras^{G12D}$ -regulated glucose metabolites, including G6P and F6P, are precursors for other glucose-utilizing pathways, namely the hexosamine biosynthesis pathway (HBP) and pentose phosphate pathway (PPP), we audited these pathways immediately following $Kras^{G12D}$ inactivation. Steady-state metabolite profiling showed a significant decrease in glucosamine-6-phosphate (GlcN-6P), the product of the committed step governing entry into HBP (Figures 5A and 5B). Correspondingly, downregulation of the rate-limiting enzyme, *Gfpt1*, was documented at the transcriptional and protein levels (Figures 5C and 5D). Moreover, the GSEA showed downregulation of O-glycosylation and glycan structure biosynthesis pathways (Figures 3B and S5A) and western blotting of cells off doxy showed a decrease in the levels of total O-linked N-acetylglucosamine (O-GlcNAc) posttranslational modification (Figure 5E),




Figure 3. Transcriptional Changes Induced by *Kras*^{G12D} Inactivation

(A) Orthotopic xenograft tumors were generated from five independent primary *iKras p53*^{L/+} PDAC cell lines. Animals were kept on doxy for 2 weeks until tumors were fully established. Half of the animals were pulled off doxy for 24 hr at which point tumor lysate was prepared. Ras activity was measured with Raf-RBD pull-down assay.

data supported by the fact that the HBP provides the substrate for O- and N-linked glycosylation. This profile of reduced glycosylation is comparable to that observed upon glucose starvation (Figure 5E) and strongly indicates that oncogenic Kras^{G12D} is essential for the maintenance of protein glycosylation in established tumors.

To further substantiate the essentiality of Kras^{G12D}-mediated control of protein glycosylation, we assessed the impact of shRNA knockdown of Gfpt1. Consistent with its pivotal role in providing protein glycosylation substrates, Gfpt1 knockdown reduced the overall O-linked glycosylation to a level similar to that of tumor cells in which Kras^{G12D} is extinguished (Figure 5F). Gfpt1 knockdown also inhibited the clonogenic and soft-agar growth of tumor cells from both the *iKras p53^{L/+}* and the *LSL-Kras^{G12D} p53^{L/+}* tumor cells (Figures 5G and 5H) and suppressed xenograft tumor growth in vivo (Figure 5I). Notably, tumors that emerged in the Gfpt1 knockdown group showed recovery of Gfpt1 expression (Figure S5B). Thus, Kras^{G12D}-mediated tumor maintenance is at least partially dependent upon its stimulation of the HBP and associated protein glycosylation.

Kras^{G12D} Promotes Ribose Biogenesis through the Nonoxidative Arm of the PPP

The PPP utilizes glucose to generate the ribose ring of DNA/RNA and to maintain cellular reducing power in the form of NADPH (Deberardinis et al., 2008b). Metabolomic profiling also revealed significant changes in several metabolites from the PPP (Figure 6A). In particular, an intermediate unique to the PPP, sedoheptulose-7-phosphate (S7P), was significantly reduced upon Kras^{G12D} extinction (Figure 6C). To further elucidate the effect of Kras^{G12D} activity on glucose catabolism through the PPP, we used U-¹³C₆-glucose to trace glucose flux into the PPP. Consistent with the steady-state data, we observed that Kras^{G12D} enhanced glycolytic flux without affecting the flux of glycolytic metabolites into the TCA cycle (Figure S6A and data not shown). Moreover, we observed a dramatic reduction in flux of U-¹³C₆-glucose into ribose-5-phosphate (R5P), S7P, and erythrose-4-phosphate (E4P), components that are unique to the nonoxidative arm of the PPP (Figure 6B). This was especially striking given that we did not observe changes in flux through the oxidative arm of the PPP (Figure 6B), nor were significant changes evident by steady-state profiling (Figure 6C). Given the link between oncogenic Kras signaling and the nonoxidative arm of the PPP, we sought to compare and quantify flux through the two arms (oxidative and nonoxidative) of the PPP.

It has been suggested that the oxidative and nonoxidative arms of the PPP can be decoupled to facilitate ribose biosynthesis without affecting the cellular redox balance (NADP⁺/NADPH ratio) (Boros et al., 1998). To explore this possibility in the context of Kras^{G12D}-driven PDAC, ¹⁴C₁- or ¹⁴C₆-labeled

glucose was used to measure the production of CO₂ from the oxidative PPP (¹⁴C₁-CO₂) relative to that generated from the glycolysis-TCA cycle route (¹⁴C₆-CO₂). Consistent with our previous data showing that Kras^{G12D} deinduction exerts a minimal effect on TCA cycle intermediates (Figure S4B), no obvious change in the release of ¹⁴C₆-CO₂ was observed upon doxy withdrawal (Figure S6B). More importantly, no significant decrease in the release of ¹⁴C₁-CO₂ was detected (Figure S6B), indicating that Kras^{G12D} extinction was not associated with decreased flux through the oxidative arm of the PPP. In addition, cellular reduced glutathione (GSH) and oxidized glutathione (GSSG) levels, which are regulated by NADPH, were not significantly altered by Kras^{G12D} inactivation, as measured by both metabolomic profiling and biochemical analysis (Figures 6C and S6C). These results provide strong evidence that Kras^{G12D} does not mediate the oxidative arm of the PPP.


To further interrogate the differential abundance of nonoxidative PPP metabolites in an oncogenic Kras-dependent manner, we traced the incorporation of individual glucose carbons using 1,2-labeled ¹³C-glucose. As shown in Figure S6D, Kras^{G12D} extinction leads to a significant decrease in 1,2-¹³C-labeled G3P and F6P (glycolytic and PPP metabolites) and the nonoxidative PPP-specific metabolites S7P and sedoheptulose 1,7-bisphosphate (SBP). Consistent with the 1,2-labeling experiment, we also observed a significant decrease of SBP upon Kras^{G12D} inactivation in the steady-state analysis (Figure 6C). SBP was recently shown to be a metabolite in the nonoxidative PPP, whose hydrolysis to S7P provides the thermodynamic driving force to propel ribose biogenesis without engaging the oxidative arm (Clasquin et al., 2011). The downregulation of SBP upon oncogene extinction implies that Kras^{G12D} may utilize this mechanism to facilitate flux through the nonoxidative arm of the PPP, although the enzyme responsible for mediating this reaction in mammals remains to be discovered.

A primary role of the nonoxidative arm of the PPP is to generate ribose-5-phosphate (R5P). As such, we hypothesized that the flux of glucose into the nonoxidative arm of the PPP by Kras^{G12D} occurs to provide tumor cells with sufficient R5P for DNA/RNA biosynthesis. To explore this possibility, we used ¹⁴C₁- or ¹⁴C₆-labeled glucose to track the contribution of oxidative versus nonoxidative PPP into DNA and RNA. Whereas ¹⁴C₆-labeled glucose will give rise to radioactive DNA/RNA whether it is used by the oxidative or the nonoxidative arm of the PPP, ¹⁴C₁-labeled glucose will only give rise to radioactive DNA/RNA if it is used by the nonoxidative arm (the ¹⁴C₁ label is lost as CO₂ through the oxidative arm; Figure S6B). As shown in Figure 6E, Kras^{G12D} extinction leads to dramatic drop in the incorporation of both ¹⁴C₁- and ¹⁴C₆-labeled glucose into DNA/RNA, clearly demonstrating a predominant and Kras^{G12D}-mediated role for the nonoxidative arm of the PPP in R5P-biogenesis. These data reveal an important role for Kras^{G12D} in

(B) Heat maps of the genes enriched in indicated metabolism pathways illustrate the changes in gene expression upon doxy withdrawal. Expression levels shown are representative of log₂ values of each replicate from either xenograft tumors or cultured parental cell lines. Red signal denotes higher expression relative to the mean expression level within the group and green signal denotes lower expression relative to the mean expression level within the group.

(C) GSEA plot of steroid biosynthesis (top), pyrimidine metabolism (middle), and O-glycan biosynthesis (bottom) pathways based on the off-doxy versus on-doxy gene expression profiles. NES denotes normalized enrichment score.

See also Figure S3.



preferential maintenance of glycolytic flux through the nonoxidative arm of the PPP in PDAC tumors.

Inhibition of the Nonoxidative PPP Suppresses $Kras^{G12D}$ -Dependent Tumorigenesis

In agreement with the specific regulation of the nonoxidative arm of the PPP, the enzymes involved in the oxidative arm, including *G6pd*, *Pgls*, and *Pgd*, as well as the enzymatic activity of *G6pd* (the rate-limiting step for the oxidative arm) were not altered upon $Kras^{G12D}$ extinction (Figures 6D and S6E). In contrast, the expression levels of *Rpia* and *Rpe*, enzymes that regulate carbon exchange reactions in the nonoxidative arm of the PPP, were significantly decreased (Figure 6D). In agreement with their roles in the nonoxidative PPP, knockdown of either *Rpia* or *Rpe*, or the combination, significantly reduced the flux of $^{14}C_1$ -labeled glucose into DNA/RNA (Figures 6F and S6F), indicating that the selective regulation of nonoxidative PPP flux by oncogenic *Kras* is, at least, partially mediated through *Rpia* and *Rpe*. More importantly, although *Rpia* or *Rpe* knockdown moderately suppresses the clonogenic activity of *iKras p53^{L/+}* tumor cells in high-glucose (11 mM), the inhibitory effect is dramatically enhanced when cells were switched to low-glucose containing media (1 mM) (Figures 6G and 6H), a condition that may reflect the decreased glucose uptake and glycolytic flux after $Kras^{G12D}$ extinction. These findings were corroborated with the decrease in xenograft tumor growth upon *Rpia* or *Rpe* knockdown (Figure 6I), further supporting the functional importance of the nonoxidative PPP during $Kras^{G12D}$ -mediated PDAC maintenance.

$Kras^{G12D}$ Reprograms Metabolism in PDAC through MAPK and Myc Pathways

To further dissect the downstream mechanism of $Kras^{G12D}$ -mediated metabolic reprogramming, we used specific pharmacological inhibitors to examine the impact of effector pathways on tumor metabolism. As shown in Figure 7A, the expression of several glycolytic genes (*Glut1*, *Hk1*, *Eno1*, *Ldha*), the rate-limiting HBP gene (*Gfpt1*), as well as a nonoxidative PPP gene (*Rpia*) are significantly decreased by MEK inhibition (AZD8330) at a dose that exerts a similar effect on ERK phosphorylation as that observed upon doxy withdrawal (Figure S7A). Consistently, MAPK inhibition recapitulated the $Kras^{G12D}$ inactivation-induced metabolite changes in the glycolysis, HBP and nonoxidative PPP pathways (Figure S7B). These data indicate that the

MAPK pathway is a major effector of oncogenic *Kras*-mediated glucose metabolism remodeling in PDAC, which is consistent with the rapid decrease of MAPK signaling upon oncogene inactivation (Figures 2B, S2C, and S2D). In contrast, although mTOR signaling is also suppressed upon $Kras^{G12D}$ inactivation, Rapamycin treatment did not induce extensive changes in glucose metabolism. In agreement with the minimal alteration in Akt signaling upon oncogene silencing (Figures S2C and S2D), inhibition of PI3K-AKT signaling (BKM120) did not exhibit a significant impact on *iKras*-directed tumor metabolism (Figures 7A, S7A, and S7B).

To gain further insight into the $Kras^{G12D}$ -mediated transcriptional regulation that facilitates metabolic reprogramming, promoter analysis was performed on differentially expressed genes upon $Kras^{G12D}$ inactivation. In silico *cis*-element analysis revealed a highly significant enrichment of the Myc binding element (Figure S7C, $p = 5.11 \times 10^{-65}$). Furthermore, Myc protein level was decreased upon $Kras^{G12D}$ inactivation or MEK inhibitor treatment (Figures S7A and S7D). Because it has been shown that Myc is required for Ras-dependent tumor maintenance (Soucek et al., 2008), we hypothesized that Myc may be a prominent mediator of the $Kras^{G12D}$ -dependent transcriptional regulation of metabolism genes. Indeed, shRNA knockdown of Myc in *iKras* PDAC cells significantly downregulated the expression of metabolism genes in the glycolysis, HBP, and nonoxidative PPP pathways (Figures S7E and S7F). Another possible candidate mediator of *Kras*-induced transcriptional changes of metabolism genes was HIF1 α . Although there was some enrichment of HIF1 α promoter elements in the *Kras* transcriptional changes, knockdown of HIF1 α had only minimal impact on metabolic enzyme expression (data not shown). Together, our data indicates that the MAPK pathway and Myc-directed transcriptional control play key roles for $Kras^{G12D}$ -mediated metabolic reprogramming in PDAC.

DISCUSSION

In this study, an inducible $Kras^{G12D}$ -driven PDAC model provided genetic evidence that oncogenic *Kras* serves a tumor maintenance role in fully established PDAC. Integrated genomic, biochemical, and metabolomic analyses immediately following $Kras^{G12D}$ extinction revealed a prominent perturbation of multiple metabolic pathways. In particular, $Kras^{G12D}$ exerts

Figure 4. $Kras^{G12D}$ Extinction Leads to Decreased Glucose Uptake and Glycolysis

(A) Summary of the changes in glycolysis upon $Kras^{G12D}$ inactivation. Metabolites that decrease upon doxy withdrawal are indicated with green arrows. Bar graphs indicate the relative expression levels of differentially expressed glycolytic enzymes that showed a significant decrease in the absence of doxy; the gene names for those enzymes that exhibited significant changes are also highlighted in the cartoon in blue. Glycolytic enzymes whose change in expression was not significant are illustrated in gray.

(B) Heat map of those metabolites that are significantly and consistently changed upon doxy withdrawal between the two *iKras p53^{L/+}* lines as determined by targeted LC-MS/MS using SRM. Cells were maintained in the presence or absence of doxy for 24 hr, at which point metabolite levels were measured from triplicates for each treatment condition. The averaged ratios of off-doxy over on-doxy levels for differentially regulated metabolites are represented in the heat map. Asterisks indicate metabolites involved in glucose metabolism that decrease upon doxy withdrawal.

(C and D) *iKras p53^{L/+}* cells were maintained in the presence or absence of doxy for 24 hr. Relative changes of glucose (C) or lactate (D) levels in the medium were measured and normalized to cell numbers.

(E) Fold changes of glycolytic intermediates upon doxy withdrawal for 24 hr. * $p < 0.05$; ** $p < 0.01$. Error bars represent SD of the mean. B(1,3)PG, 1,3-bisphosphoglycerate; B(2,3)PG, 2,3-bisphosphoglycerate; DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; G6P, glucose 6-phosphate; G3P, glyceraldehyde 3-phosphate; PEP, phosphoenolpyruvate; 3PG, 3-phosphoglycerate.

See also Figure S4.




Figure 5. Kras^{G12D} Inactivation Leads to Inhibition of the Hexosamine Biosynthesis Pathway and Protein O-Glycosylation
 (A) Summary of changes in the HBP upon Kras^{G12D} inactivation. Metabolites that decrease upon doxy withdrawal are indicated with green arrows. Differentially expressed genes upon doxy withdrawal are highlighted in blue.
 (B) Fold change of metabolites in the HBP upon doxy withdrawal for 24 hr.
 (C and D) Relative mRNA (C) and protein levels (D) of Gfpt1 in the presence or absence of doxy for 24 hr.

potent control of glycolysis through regulation of glucose transporter and several rate-limiting enzymes at the transcriptional level, which collectively serve to shunt glucose metabolism toward anabolic pathways, such as HBP for protein glycosylation and PPP for ribose production (Figure 7B). Notably, we identified an unexpected connection between oncogenic Kras and the nonoxidative arm of the PPP, which functions to provide precursors for DNA and RNA biosynthesis. The functional validation of several Kras^{G12D}-regulated metabolic enzymes provide candidate therapeutic targets and associated biomarkers for the signature oncogene in this intractable disease.

Kras^{G12D} Is Required for PDAC Maintenance

Studies in multiple GEMMs have shown that tumor maintenance is often dependent on the driver oncogene that initiates tumor development (Chin et al., 1999; Felsner and Bishop, 1999; Fisher et al., 2001; Moody et al., 2002). However, recent in vitro studies in human PDAC cell lines have indicated that certain pancreatic cell lines expressing mutant Kras may lose dependence on this oncogene (Singh et al., 2009), raising the question whether oncogenic Kras remains relevant to tumor maintenance in advanced PDAC in the in vivo setting. In our study, the observation of a complete regression of fully established tumors ~1 week upon Kras^{G12D} extinction underscores the essential role of this signature oncogene in PDAC, although we cannot exclude the possibility that residual cancer cells may remain. Additionally, our data uncovers a key relationship between the oncogenic Kras-expressing tumor cells and the prominent desmoplastic stroma that is characteristic of PDAC. Upon Kras extinction, there is a rapid reduction in SMA-positive pancreatic stellate cells. Recent work has shown a correlation between stromal SMA positivity and poor prognosis in PDAC patients (Fujita et al., 2010). It is tempting to speculate that Kras^{G12D} may promote the paracrine secretion of prostromal factors such as Sonic Hedgehog (Neesse et al., 2011); however, further work will be necessary to define this complex relationship.

Oncogenic Kras^{G12D} Directs Glucose Metabolism into Biosynthetic Pathways in PDAC

The reprogramming of cellular metabolism to support continuous proliferation is a hallmark of cancer (Hanahan and Weinberg, 2011). Our analysis in vivo following Kras^{G12D} extinction showed rapid downregulation of specific metabolic enzymes and their pathways prior to any discernible biological impact (e.g., morphological or proliferative changes), a finding consistent with the active control of tumor cell metabolism by Kras^{G12D}. Indeed, the Kras oncogene is known to induce aerobic glycolysis (Racker et al., 1985), and PDAC cells have been shown previ-

ously to have metabolism consistent with elevated aerobic glycolysis (Zhou et al., 2011). Interestingly, this metabolic switch may be dependent on cell type or oncogenic Ras isoform as H-Ras transformed mesenchymal stem cells do not depend on increased glycolysis for ATP production during transformation (Funes et al., 2007).

The striking and specific transcriptional alteration of metabolic gene expression, which shows high concordance with the actual changes in metabolism, adds to the well-established means of metabolic regulation by allosteric effects on rate-limiting enzymes. Our findings underscore the relevance of gene expression as a mechanism to achieve metabolic reprogramming in tumor cells to determine the metabolic flux route and rate (DeBerardinis et al., 2008a). Another important feature of such transcriptional regulation is that the rewiring of metabolism pathways by the Kras oncogene is achieved through the highly coordinated control over multiple nodes, including rate-limiting enzymes.

Our work establishes that Kras^{G12D} extinction leads to inhibition of glucose uptake and a decrease in several glycolytic intermediates, including G6P, F6P, and FBP. Although aerobic glycolysis is recognized as inefficient from a bioenergetics perspective, metabolic reprogramming to a glycolytic state has been proposed as a mechanism which allows the allocation of glycolytic intermediates into biosynthetic pathways (Vander Heiden et al., 2009). Indeed, we have demonstrated the enhanced glycolytic flux is diverted into the nonoxidative PPP to facilitate ribose biogenesis. Furthermore, such hypotheses are also supported by the observation that amplification/overexpression of *PHGDH*, a rate-limiting enzyme functioning to divert 3-phosphoglycerate (a glycolytic intermediate) into the serine biosynthesis pathway, facilitates tumor growth in certain contexts (Locasale et al., 2011; Possemato et al., 2011).

The Activation of Hexosamine Biosynthesis and Glycosylation Pathways by Kras^{G12D}

In this study, we provide evidence that oncogenic Kras plays a prominent role in the flux of glucose into the HBP. Our data shows that the expression of Gfpt1, the first and rate-limiting step of HBP, is strongly downregulated upon Kras^{G12D} inactivation. The HBP is obligatory for various glycosylation processes, such as protein N- or O-glycosylation and glycolipid synthesis. Although its function during tumorigenesis is poorly understood, recent studies indicate that the HBP is important for the coordination of nutrient uptake, partially through modulating the glycosylation and membrane localization of growth factor receptors (Wellen et al., 2010). Protein and lipid glycosylation is an abundant posttranslational modification and plays fundamental regulatory roles in tumor cell proliferation, invasion/metastasis,

(E) Western blot analysis for O-linked N-acetylglucosamine (O-GlcNAc) levels in cells maintained in the presence or absence of doxy for 24 hr. For control samples, MEFs were cultured in the presence or absence of glucose for 24 hr.

(F) Western blot analysis for O-GlcNAc and Gfpt1 levels in cells infected with shRNA against GFP or Gfpt1.

(G and H) Clonogenic assay (G) and soft-agar colony formation assay (H) for *iKras p53^{L/+}* or *LSL-Kras p53^{L/+}* PDAC cells infected with shRNA against GFP or Gfpt1.

(I) *iKras p53^{L/+}* cell lines were infected with shRNA against GFP or Gfpt1 and subcutaneously injected into nude mice. Tumor volumes were measured and data shown are representative of results from three independent cell lines. *p < 0.05; **p < 0.01.

Error bars represent SD of the mean. GlcNAc-1P, N-acetylglucosamine 1-phosphate; GlcNAc-6P, N-acetylglucosamine 6-phosphate; GlcN6P, glucosamine 6-phosphate; UDP-GlcNAc, UDP-N-acetylglucosamine. See also Figure S5.




Figure 6. *Kras*^{G12D} Preferentially Enhances Nonoxidative PPP to Support Ribose Biogenesis

(A) Summary of changes in the PPP upon *Kras*^{G12D} inactivation. Metabolites that decrease upon doxy withdrawal are indicated with green arrows. Differentially expressed genes upon doxy withdrawal are highlighted in blue.

(B) *iKras* *p53*^{L/+} cells were maintained in the presence or absence of doxy for 24 hr, at which point U-¹³C glucose labeling kinetics for the indicated metabolites were compared at 1, 3, and 10 min.

(C) Fold changes for metabolites in the PPP upon doxy withdrawal for 24 hr.




Figure 7. MAPK Pathway Is Critical for $Kras^{G12D}$ -Mediated Metabolism Reprogramming

(A) *iKras p53^{L/+}* cells were treated with AZD8330 (50 nM), BKM120 (150 nM), or Rapamycin (20 nM) for 18 hr. In parallel, cells were cultured in the presence or absence of doxy for 24 hr to serve as controls and relative mRNA levels of indicated metabolism genes were measured by QPCR. Error bars represent SD of the mean. * $p < 0.05$; ** $p < 0.01$.

(B) Schematic representation of the shift in glucose metabolism upon $Kras^{G12D}$ withdrawal. Activation of oncogenic $Kras$ enables PDAC tumor maintenance through the increased uptake of glucose and subsequent shunting into glycolysis, the HBP pathway (to enable enhanced glycosylation) and the nonoxidative arm of the PPP (to facilitate ribose biosynthesis for DNA/RNA). Glucose flux into the oxidative arm of the PPP and the TCA cycle do not change when $Kras^{G12D}$ is inactivated.

angiogenesis, and immune evasion (Fuster and Esko, 2005; Hart and Copeland, 2010). Ras oncogenes have been shown to induce N-glycosylation and $Kras$ mutation in human colorectal cancer cells is associated with increased N-linked carbohydrate branching (Bolscher et al., 1988; Dennis et al., 1989; Rak et al., 1991; Wojciechowicz et al., 1995). Here, we provided additional evidence that oncogenic $Kras$ signaling also sustains protein O-glycosylation during tumor maintenance.

$Kras^{G12D}$ Induces Nonoxidative PPP Flux

The PPP is considered important for tumorigenesis as it provides NADPH for macromolecule biosynthesis and ROS detoxification, as well as ribose 5-phosphate for DNA/RNA synthesis (Boros et al., 1998; Deberardinis et al., 2008b). Additionally, it has been shown that the Ras oncogene promotes resistance to oxidative stress through GSH-based ROS scavenger pathways (DeNicola et al., 2011; Recktenwald et al., 2008), and this is likely mediated in part by the production of NADPH through the oxidative arm of the PPP. In fact, the oxidative arm of the PPP has been shown to be activated by $Kras$ oncogene-mediated

transformation to promote cell proliferation (Vizan et al., 2005; Weinberg et al., 2010). Notably, we did not observe obvious changes in the oxidative PPP but rather a role for oncogenic $Kras$ signaling in the preferential maintenance of the nonoxidative arm of PPP. It has been recently shown that p53 inhibits G6PD activity through direct binding (Jiang et al., 2011). Therefore, it is possible that the oxidative PPP is largely regulated by p53 deficiency in PDAC tumor cells, whereas oncogenic signaling from $Kras^{G12D}$ sustains the nucleotide pool through de novo biosynthetic pathways. Indeed, recent evidence suggests that the nonoxidative PPP is preferentially upregulated in tumor cells including pancreatic cancer (Boros et al., 2005; Tong et al., 2009). Our data indicate that such metabolic changes are tightly regulated by oncogenic $Kras$ and that suppression of the nonoxidative PPP blocks tumorigenic activity. These data suggest that inhibition of early steps of nucleotide biosynthesis, such as R5P production, could provide a useful therapeutic strategy for $Kras^{G12D}$ mutant tumors.

One interesting observation of $Kras^{G12D}$ -mediated metabolic reprogramming is the decrease in SBP upon $Kras^{G12D}$ inactivation. Interestingly, an enzyme was recently discovered in yeast that dephosphorylates SBP thereby providing the thermodynamic driving force for canonical F-type nonoxidative PPP flux independent of the oxidative arm (Clasquin et al., 2011).

(D) Relative mRNA levels of PPP genes in the presence or absence of doxy for 24 hr.

(E) *iKras p53^{L/+}* cells were maintained in the presence or absence of doxy for 24 hr, followed by a 24 hr labeling with 1-¹⁴C or 6-¹⁴C glucose. Incorporation of radioactivity into DNA or RNA were determined and normalized to DNA or RNA concentration.

(F) *iKras p53^{L/+}* cells were infected with shRNA against Rpia and Rpe individually or in combination. shRNA against GFP was used as a control. Cells were labeled with 1-¹⁴C glucose and incorporation of radioactivity into DNA and RNA was determined as in (E).

(G) *iKras p53^{L/+}* cells were maintained under high (11 mM) or low (1 mM) glucose, and clonogenic activity was determined for cells infected with shRNA against GFP, Rpia, or Rpe.

(H) Quantification of colony numbers.

(I) *iKras p53^{L/+}* cells were infected with shRNA against GFP, Rpia, or Rpe and subcutaneously injected into nude mice. Tumor volumes were measured and data shown are representative of results from three independent cell lines.

Error bars represent SD of the mean. * $p < 0.05$; ** $p < 0.01$. E4P, erythrose 4-phosphate; G6L6P, 6-phosphoglucono- δ -lactone; GSH, reduced glutathione; GSSG, oxidized glutathione; 6PG, 6-phosphogluconate; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate; SBP, sedoheptulose 1,7-bisphosphate; X5P, xylulose 5-phosphate. See also Figure S6.

However, attempts at identifying a mammalian ortholog have been unsuccessful. Alternatively, SBP has also been reported to function in an alternative “L-type” PPP in liver that eventually feeds into the nonoxidative arm (Williams et al., 1987). Our finding provides a unique connection of this pathway to a driver oncogene and may provide a novel diagnostic and therapeutic avenue for these Ras-driven tumors.

EXPERIMENTAL PROCEDURES

Generation of Plasmid Construct and Transgenic Mice

A fragment containing mutant murine *Kras*^{G12D} cDNA (Johnson et al., 2001) was used to generate the *tetO-Lox-Stop-Lox-Kras*^{G12D} transgene by standard cloning methods. The detailed method and additional alleles are described in Extended Experimental Procedures. All manipulations were performed under IACUC approval protocol number 04116.

Xenograft Studies

For orthotopic xenografts, 5×10^5 cells suspended in 10 μ l 50% Matrigel (BD Biosciences)/Hanks buffered saline solution were injected pancreatically into NCr nude mice (Taconic). Animals were fed with doxy water.

For Sub-Q xenografts, 1×10^6 cells suspended in 100 μ l Hanks buffered saline solution were injected subcutaneously into the lower flank of NCr nude mice (Taconic). Animals were fed with doxy water. Tumor volumes were measured every 3 days starting from Day 4 postinjection and calculated using the formula, volume = length \times width²/2. All xenograft experiments were approved under IACUC protocol 04114.

Immunohistochemistry and Western Blot Analysis

Tissues were fixed in 10% formalin overnight and embedded in paraffin. Immunohistochemical analysis was performed as described (Aguirre et al., 2003). The primary antibodies used for immunohistochemistry or western are listed in Extended Experimental Procedures.

Targeted Mass Spectrometry

The preparation and measurement of metabolites by LC-MS/MS are described in Extended Experimental Procedures.

Isotope Labeling and Kinetic Profiling

Glucose- or glutamine-free RPMI was supplemented with 10% dialyzed serum and 1,2-¹³C₂-glucose, U-¹³C₆-glucose, or U-¹³C₅-glutamine (Cambridge Isotope Labs) to 11 mM (for glucose) or 2 mM (for glutamine). Cells were maintained in the presence or absence of doxy for 24 hr, at which point labeled media was added to biological triplicates. For glucose-flux analysis, cells were maintained in the presence or absence of doxy for 24 hr and then media was replaced with that containing U-¹³C₆-glucose.

¹⁻¹⁴C/⁶⁻¹⁴C Glucose Incorporation into Nucleotides

Cells were maintained in the presence or absence of doxy for 24 hr, at which point biological triplicates were treated with 1 μ Ci ¹⁻¹⁴C or ⁶⁻¹⁴C glucose. Cells were harvested 24 hr later. DNA or RNA were isolated with QIAGEN kits according to the manufacturer's instructions and quantified using a NanoDrop instrument. Equal volumes of DNA/RNA were added to scintillation vials and radioactivity was measured by liquid scintillation counting and normalized to the DNA/RNA concentration.

¹⁴C Glucose Incorporation into CO₂

Cells were maintained in the presence or absence of doxy for 24 hr, at which point biological triplicates were treated with 1 μ Ci ¹⁻¹⁴C or ⁶⁻¹⁴C glucose and incubated at 37°C for the indicated time points. To release ¹⁴CO₂, 150 μ l of 3 M perchloric acid was added to each well and immediately covered with phenylethylamine saturated Whatman paper and incubated at room temperature overnight. The Whatman paper was then analyzed by scintillation counting.

Metabolite Analysis of Spent Medium

Cells were seeded in 12-well plates in triplicate for 24 hr followed by culture in doxy-free medium or medium containing doxy for additional 24 hr. Glucose and lactate concentrations were measured in fresh and spent medium using a Yellow Springs Instruments (YSI) 7100. Glucose data are presented as net decrease in concentration, and lactate as net increase in concentration after normalization to cell numbers.

Expression Profiling and Bioinformatics Analysis

mRNA expression profiling and data analysis are described in Extended Experimental Procedures.

Lentiviral-Mediated shRNA Targeting

Lentiviral shRNA clones targeting Gfpt1, Rpia, Rpe, and nontargeting control construct shGFP were obtained from the RNAi Consortium at the Dana-Farber/Broad Institute. The clone IDs for the shRNA are listed in Extended Experimental Procedures.

Statistical Analysis

Tumor-free survivals were analyzed using GraphPad Prism4. Statistical analyses were performed using nonparametric Mann-Whitney test. Other comparisons were performed using the unpaired Student's t test. For all experiments with error bars, standard deviation (SD) was calculated to indicate the variation within each experiment and data, and values represent mean \pm SD.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, seven figures, and one table and can be found with this article online at doi:10.1016/j.cell.2012.01.058.

ACKNOWLEDGMENTS

We thank Christopher Wright for the p48-Cre mice; Shan Zhou and Shan Jiang for expert monitoring of the mouse colony; Yingchun Liu, Yuxiang Zheng, Ning Wu, Alexandra Grassian, Joan Brugge, Min Yuan, and Susanne Breitkopf for helpful suggestions and technical support. Grant support derives from NIH grants T32 CA009382-26 (H.Y.) and P01 CA117969 (R.W., L.C., L.C.C., R.A.D.). Imaging was supported by U24 CA092782 and P50 CA86355 (R.W.). Mass spectrometry was supported by 5P01CA120964-05 (L.C.C. and J.A.), 5P30CA006516-46 (J.A.), and the BIDMC Research Capital Fund. A.C.K. is supported by the National Cancer Institute Grant R01 CA157490, Kimmel Scholar Award and AACR-PanCAN Career Development Award. C.A.L. is the Amgen Fellow of the Damon Runyon Cancer Research Foundation (DRG-2056-10). S.H. is supported by a Damon Runyon Fellowship. A.C.K. is a Consultant for Forma Therapeutics. L.C.C. is a founder of Agios Pharmaceuticals, a company developing drugs to target metabolic enzymes for cancer therapy.

Received: September 23, 2011

Revised: December 12, 2011

Accepted: January 30, 2012

Published: April 26, 2012

REFERENCES

- Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., and DePinho, R.A. (2003). Activated *Kras* and *Ink4a/Arf* deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. *Genes Dev.* 17, 3112–3126.
- Belteki, G., Haigh, J., Kabacs, N., Haigh, K., Sison, K., Costantini, F., Whitsett, J., Quaggin, S.E., and Nagy, A. (2005). Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. *Nucleic Acids Res.* 33, e51.
- Bolscher, J.G., van der Bijl, M.M., Neeffjes, J.J., Hall, A., Smets, L.A., and Ploegh, H.L. (1988). Ras (proto)oncogene induces N-linked carbohydrate

- modification: temporal relationship with induction of invasive potential. *EMBO J.* 7, 3361–3368.
- Boros, L.G., Lee, P.W., Brandes, J.L., Cascante, M., Muscarella, P., Schirmer, W.J., Melvin, W.S., and Ellison, E.C. (1998). Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? *Med. Hypotheses* 50, 55–59.
- Boros, L.G., Lerner, M.R., Morgan, D.L., Taylor, S.L., Smith, B.J., Postier, R.G., and Brackett, D.J. (2005). [1,2-¹³C₂]-D-glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. *Pancreas* 31, 337–343.
- Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999). Essential role for oncogenic Ras in tumour maintenance. *Nature* 400, 468–472.
- Clasquin, M.F., Melamud, E., Singer, A., Gooding, J.R., Xu, X., Dong, A., Cui, H., Campagna, S.R., Savchenko, A., Yakunin, A.F., et al. (2011). Riboneogenesis in yeast. *Cell* 145, 969–980.
- DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008a). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab.* 7, 11–20.
- DeBerardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B. (2008b). Brick by brick: metabolism and tumor cell growth. *Curr. Opin. Genet. Dev.* 18, 54–61.
- DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* 475, 106–109.
- Dennis, J.W., Kosh, K., Bryce, D.M., and Breitman, M.L. (1989). Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. *Oncogene* 4, 853–860.
- Felsher, D.W., and Bishop, J.M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. *Mol. Cell* 4, 199–207.
- Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. *Genes Dev.* 15, 3249–3262.
- Fujita, H., Ohuchida, K., Mizumoto, K., Nakata, K., Yu, J., Kayashima, T., Cui, L., Manabe, T., Ohtsuka, T., and Tanaka, M. (2010). alpha-Smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. *Pancreas* 39, 1254–1262.
- Funes, J.M., Quintero, M., Henderson, S., Martinez, D., Qureshi, U., Westwood, C., Clements, M.O., Bourbouli, D., Pedley, R.B., Moncada, S., and Boshoff, C. (2007). Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. *Proc. Natl. Acad. Sci. USA* 104, 6223–6228.
- Fuster, M.M., and Esko, J.D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. *Nat. Rev. Cancer* 5, 526–542.
- Gao, P., Tchernyshyov, I., Chang, T.C., Lee, Y.S., Kita, K., Ochi, T., Zeller, K.I., De Marzo, A.M., Van Eyk, J.E., Mendell, J.T., and Dang, C.V. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* 458, 762–765.
- Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., and Barbacid, M. (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer Cell* 4, 111–120.
- Gysin, S., Salt, M., Young, A., and McCormick, F. (2011). Therapeutic strategies for targeting ras proteins. *Genes Cancer* 2, 359–372.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- Hart, G.W., and Copeland, R.J. (2010). Glycomics hits the big time. *Cell* 143, 672–676.
- Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev.* 20, 1218–1249.
- Hidalgo, M. (2010). Pancreatic cancer. *N. Engl. J. Med.* 362, 1605–1617.
- Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 4, 437–450.
- Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., and Yang, X. (2011). p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. *Nat. Cell Biol.* 13, 310–316.
- Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 410, 1111–1116.
- Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and Wright, C.V. (2002). The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat. Genet.* 32, 128–134.
- Levine, A.J., and Puzio-Kuter, A.M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. *Science* 330, 1340–1344.
- Locasale, J.W., Grassian, A.R., Melman, T., Lyssiotis, C.A., Mattaini, K.R., Bass, A.J., Heffron, G., Metallo, C.M., Muranen, T., Sharfi, H., et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. *Nat. Genet.* 43, 869–874.
- Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J., and Berns, A. (2000). Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev.* 14, 994–1004.
- Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan, K.D., Innocent, N., Cardiff, R.D., Schnell, M.D., and Chodosh, L.A. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. *Cancer Cell* 2, 451–461.
- Neesse, A., Michl, P., Frese, K.K., Feig, C., Cook, N., Jacobetz, M.A., Lolkema, M.P., Buchholz, M., Olive, K.P., Gress, T.M., and Tuveson, D.A. (2011). Stromal biology and therapy in pancreatic cancer. *Gut* 60, 861–868.
- Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. *Nature* 476, 346–350.
- Racker, E., Resnick, R.J., and Feldman, R. (1985). Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. *Proc. Natl. Acad. Sci. USA* 82, 3535–3538.
- Rak, J.W., Basolo, F., Elliott, J.W., Russo, J., and Miller, F.R. (1991). Cell surface glycosylation changes accompanying immortalization and transformation of normal human mammary epithelial cells. *Cancer Lett.* 57, 27–36.
- Recktenwald, C.V., Kellner, R., Lichtenfels, R., and Seliger, B. (2008). Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. *Cancer Res.* 68, 10086–10093.
- Rinehart, J., Adjei, A.A., Lorusso, P.M., Waterhouse, D., Hecht, J.R., Natale, R.B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E.P., et al. (2004). Multi-center phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. *J. Clin. Oncol.* 22, 4456–4462.
- Singh, A., and Settleman, J. (2009). Oncogenic K-ras “addiction” and synthetic lethality. *Cell Cycle* 8, 2676–2677.
- Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., and Settleman, J. (2009). A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. *Cancer Cell* 15, 489–500.
- Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Modelling Myc inhibition as a cancer therapy. *Nature* 455, 679–683.

- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* *102*, 15545–15550.
- Tong, X., Zhao, F., and Thompson, C.B. (2009). The molecular determinants of de novo nucleotide biosynthesis in cancer cells. *Curr. Opin. Genet. Dev.* *19*, 32–37.
- Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* *324*, 1029–1033.
- Vizan, P., Boros, L.G., Figueras, A., Capella, G., Manges, R., Bassilian, S., Lim, S., Lee, W.N., and Cascante, M. (2005). K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. *Cancer Res.* *65*, 5512–5515.
- Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G.M., Budinger, G.R., and Chandel, N.S. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc. Natl. Acad. Sci. USA* *107*, 8788–8793.
- Wellen, K.E., Lu, C., Mancuso, A., Lemons, J.M., Ryczko, M., Dennis, J.W., Rabinowitz, J.D., Collier, H.A., and Thompson, C.B. (2010). The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes Dev.* *24*, 2784–2799.
- Williams, J.F., Arora, K.K., and Longenecker, J.P. (1987). The pentose pathway: a random harvest. Impediments which oppose acceptance of the classical (F-type) pentose cycle for liver, some neoplasms and photosynthetic tissue. The case for the L-type pentose pathway. *Int. J. Biochem.* *19*, 749–817.
- Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer, H.K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S.B., and Thompson, C.B. (2008). Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc. Natl. Acad. Sci. USA* *105*, 18782–18787.
- Wojciechowicz, D.C., Park, P.Y., and Paty, P.B. (1995). Beta 1-6 branching of N-linked carbohydrate is associated with K-ras mutation in human colon carcinoma cell lines. *Biochem. Biophys. Res. Commun.* *212*, 758–766.
- Yuan, M., Breitkopf, S.B., and Asara, J.M. (2012). A positive/negative switching targeted mass spectrometry based metabolomics platform for bodily fluids, cells, fresh and fixed tissue. *Nat. Protoc.*, in press.
- Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J.K., Markowitz, S., Zhou, S., et al. (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* *325*, 1555–1559.
- Zhou, W., Capello, M., Fredolini, C., Piemonti, L., Liotta, L.A., Novelli, F., and Petricoin, E.F. (2011). Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. *J. Proteome Res.* *10*, 1944–1952.